ArticlePloS one2024

TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma.

Qinghong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.